Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy

Arginine Starvation Impairs Mitochondrial Respiratory Function in ASS1-Deficient Breast Cancer Cells

(2014) F. Qiu et al.   Science Signaling

Targeting Arginine-Dependent Cancers with Arginine-Degrading Enzymes: Opportunities and Challenges

(2014) Melissa M. Phillips et al.   Cancer Research and Treatment

Prognostic and Therapeutic Impact of Argininosuccinate Synthetase 1 Control in Bladder Cancer as Monitored Longitudinally by PET Imaging

(2013) M. D. Allen et al.   CANCER RESEARCH

ASS1 as a Novel Tumor Suppressor Gene in Myxofibrosarcomas: Aberrant Loss via Epigenetic DNA Methylation Confers Aggressive Phenotypes, Negative Prognostic Impact, and Therapeutic Relevance

(2013) H.-Y. Huang et al.   CLINICAL CANCER RESEARCH

Tumour heterogeneity in the clinic

(2013) Philippe L. Bedard et al.   NATURE

Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma

(2013) N Syed et al.   Cell Death & Disease

Novel Pathways and Molecular Targets for the Treatment of Sarcoma

(2013) Ashley E. Frith et al.   Current Oncology Reports

Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase

(2012) L G Feun et al.   BRITISH JOURNAL OF CANCER

Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma

(2012) Patrick A. Ott et al.   INVESTIGATIONAL NEW DRUGS

Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis

(2012) B Delage et al.   Cell Death & Disease

Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase

(2011) M P Kelly et al.   BRITISH JOURNAL OF CANCER

A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients

(2010) T-S Yang et al.   BRITISH JOURNAL OF CANCER

Arginine Deprivation, Autophagy, Apoptosis (AAA) for the Treatment of Melanoma

(2010) N. Savaraj et al.   CURRENT MOLECULAR MEDICINE

Phase II Study of Pegylated Arginine Deiminase for Nonresectable and Metastatic Hepatocellular Carcinoma

(2010) Evan S. Glazer et al.   JOURNAL OF CLINICAL ONCOLOGY

Reduced Argininosuccinate Synthetase Is a Predictive Biomarker for the Development of Pulmonary Metastasis in Patients with Osteosarcoma

(2010) E. Kobayashi et al.   MOLECULAR CANCER THERAPEUTICS

Arginine Deiminase as a Novel Therapy for Prostate Cancer Induces Autophagy and Caspase-Independent Apoptosis

(2009) R. H. Kim et al.   CANCER RESEARCH

Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer

(2009) Linda J. Nicholson et al.   INTERNATIONAL JOURNAL OF CANCER

Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1 /Sp4

(2009) W.-B. Tsai et al.   MOLECULAR CANCER THERAPEUTICS

Arginine Deprivation as a Targeted Therapy for Cancer

(2008) L. Feun et al.   CURRENT PHARMACEUTICAL DESIGN

Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase

(2008) Tawnya L. Bowles et al.   INTERNATIONAL JOURNAL OF CANCER